ARVINAS, INC. Earnings Per Share, Basic and Diluted
ARVINAS, INC. (ARVN) reported Earnings Per Share, Basic and Diluted of -$0.94 per share for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-11-03
- ARVINAS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.94.
- ARVINAS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.03.
- ARVINAS, INC. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.84.
- ARVINAS, INC. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.79.
- ARVINAS, INC. earnings per share, basic and diluted for fiscal 2020 was -$3.02.
- ARVINAS, INC. earnings per share, basic and diluted for fiscal 2019 was -$2.13.
- ARVINAS, INC. earnings per share, basic and diluted for fiscal 2018 was -$25.45.
- ARVINAS, INC. earnings per share, basic and diluted for fiscal 2017 was -$15.08.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-09-30 | -$0.94 10-Q · filed 2021-11-03 | -$2.81 10-Q · filed 2021-11-03 | ||
| 2021-06-30 | -$1.03 10-Q · filed 2021-08-05 | -$1.87 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | -$0.84 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | -$3.02 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$0.79 10-Q · filed 2021-11-03 | -$2.01 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$0.65 10-Q · filed 2021-08-05 | -$1.22 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$0.56 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | -$0.56 10-K · filed 2020-03-16 | -$1.11 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$1.65 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$2.13 10-K · filed 2021-03-01 |
| 2019-09-30 | -$0.54 10-Q · filed 2020-11-05 | -$1.09 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$1.54 10-Q · filed 2020-11-05 | -$2.06 derived: net income ÷ weighted average shares · filed 2020-11-05 |
| 2019-06-30 | -$0.55 10-Q · filed 2020-08-04 | -$1.01 10-Q · filed 2020-08-04 | -$1.52 derived: net income ÷ weighted average shares · filed 2020-08-04 | -$7.22 derived: net income ÷ weighted average shares · filed 2020-08-04 |
| 2019-03-31 | -$0.46 10-Q · filed 2020-04-28 | -$0.98 derived: net income ÷ weighted average shares · filed 2020-04-28 | -$7.26 derived: net income ÷ weighted average shares · filed 2020-04-28 | -$10.77 derived: net income ÷ weighted average shares · filed 2020-04-28 |
| 2018-12-31 | -$0.52 10-K · filed 2020-03-16 | -$8.55 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$14.07 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$25.45 10-K · filed 2021-03-01 |
| 2018-09-30 | -$62.38 10-K · filed 2020-03-16 | -$75.80 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$115.62 10-Q · filed 2019-11-04 | -$121.01 derived: net income ÷ weighted average shares · filed 2020-03-16 |
| 2018-06-30 | -$11.96 10-K · filed 2020-03-16 | -$51.81 10-Q · filed 2019-08-05 | -$56.72 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$60.09 derived: net income ÷ weighted average shares · filed 2020-03-16 |
| 2018-03-31 | -$39.86 10-K · filed 2020-03-16 | -$44.76 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$48.13 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$51.65 derived: net income ÷ weighted average shares · filed 2020-03-16 |
| 2017-12-31 | -$4.90 10-K · filed 2019-03-26 | -$8.27 derived: net income ÷ weighted average shares · filed 2019-03-26 | -$11.79 derived: net income ÷ weighted average shares · filed 2019-03-26 | -$15.08 10-K · filed 2019-03-26 |
| 2017-09-30 | -$3.37 10-K · filed 2019-03-26 | -$6.89 derived: net income ÷ weighted average shares · filed 2019-03-26 | -$10.18 10-Q · filed 2018-11-14 | |
| 2017-06-30 | -$3.52 10-K · filed 2019-03-26 | -$6.81 derived: net income ÷ weighted average shares · filed 2019-03-26 | ||
| 2017-03-31 | -$3.29 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |